Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Ovarian Cancer Recurrent × 30 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 407 Carcinoma, Non-Small-Cell Lung 360 Neoplasms 353 Prostatic Neoplasms 256 Lung Neoplasms 214 Colorectal Neoplasms 209 Neoplasm Metastasis 207 Multiple Myeloma 175 Leukemia, Myeloid, Acute 166 Ovarian Neoplasms 153 Recurrence 133 Melanoma 131 Squamous Cell Carcinoma of Head and Neck 129 Pancreatic Neoplasms 129 Carcinoma, Hepatocellular 107 Carcinoma, Renal Cell 105 Brain Neoplasms 105 Glioblastoma 103 Stomach Neoplasms 94 Triple Negative Breast Neoplasms 92 Endometrial Neoplasms 92 Lymphoma, Non-Hodgkin 91 Lymphoma, Large B-Cell, Diffuse 90 Urinary Bladder Neoplasms 88 Head and Neck Neoplasms 87 Leukemia, Lymphocytic, Chronic, B-Cell 85 Glioma 84 Lymphoma 81 Precursor Cell Lymphoblastic Leukemia-Lymphoma 80 Hematologic Neoplasms 75

Interventions

pembrolizumab 1 Paclitaxel 1 Carboplatin 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06843447 2026-03-27

MK-5909-003

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting

Ovarian Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon ⚡